medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2014, Number 3

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2014; 30 (3)

Use of mesenchymal stem cells in kidney transplant

Morera BLM, Socarrás FBB, Bencomo HA, González-Mugica RR

Language: Spanish
References: 12
Page: 294-297
PDF size: 47.11 Kb.


Text Extraction

No abstract.


REFERENCES

  1. Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB. Strategies to improve long-term outcomes after renal transplantation. New Engl J Med. 2002 Feb 21;346(8):580-90.

  2. Meier-Kriesche Hu, Schold JD, Srinivas TR, Kaplan B. Lack of improvements in renal allograft survival despite a marker decrease in acute rejection rates over the most recent era. Am J Trasplant 2004 Mar;4(3):378-83.

  3. Mármol A, Pérez A, Pérez de Prado JC, Herrera M, Molina S, Parodis Y, et al. Trasplante renal en Cuba. Rev Cubana Med [revista en la Internet]. 2005 Abr [citado 2014 Ene 25];44(1-2). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034- 75232005000200010&lng=es

  4. Blanco P, Robey PG, Simmons PJ. Mesenchymal stem cells: revisiting history concepts and assays. Cell Stem Cell. 2008 Apr 10;2(4):313-9. doi:10.1016/j.stem.2008.03.002

  5. Chiesa S, Morbelli S, Morando S, Masollo M, Marini C, Bertoni A, et al. Mesenchymal stem cells impair in vivo T-cell priming by dendritic cells. Proc Natl Acad Sci U S A. 2011 Oct 18;108(42):17384-9. doi:10.1073/pnas.1103650108

  6. Ringden O, Uzunel M, Rasmusson J, Remberger M, Sundberg B, Lonnies H, et al. Mesenchymal stem cells for treatment of therapy-resistant-graft-versus-host disease. Transplantation. 2006 May 27;81(10):1390-7.

  7. Alagesan S, Griffin MD. Autologous and allogeneic mesenchymal stem cells in organ transplantation: what do we know about their safety and efficacy? Curr Opin Organ Transplant. 2014 Feb;19(1):65-72.

  8. Tan J, Wu W, Xu X,Liao L, Zheng F, Messinger S. Induction therapy with autologous mesenchymal stem cells in living-related Kidney Transplantation: a randomized controlled trial. JAMA. 2012 Mar 21;307(11):1169-77. doi:10.1001/jama.2012.316

  9. Peng Y, Ke M, Xu L, Liu L, Chen X, Xia W. Donor-derived mesenchymal stem cells combined with low-dose tracrolimus prevente acute rejection after renal transplantation: a clinical pilot study. Transplantation. 2012 Jan;95(1):161-8.

  10. Lee H, ParkJB, Lee S, Baek S, Kim H, Kim SJ. Intra-osseus injection of donor mesenchymal stem cell (MSC) into the bone marrow in living donor kidney trasplantantion: a pilot study. J Transl Med. 2013 Apr 11;11:96. doi:10.1186/1479- 5876-11-96

  11. Waanders MM, Rorlen DL, Brand A, Claas FH. The putative mechanism of immunomodulating effect of HLA DR shared allogenic blood trasfusions on alloimmune response.Trasfus Med Rev. 2005 Oct;19(4):281-7.

  12. Saadi G, Fadel F, El Ansary M, El-Hamid SA. Mesenchymal stem cell trasfusion for desensitization of positive lymphocyte crooss-match before Kidney Trasplantation: outcome of 3 cases. Cell Prolif. 2013 Apr;46(2):121-6. doi:10.1111/cpr.12012




2020     |     www.medigraphic.com